WO1996033678A1 - Triacetin as a transdermal penetration enhancer - Google Patents
Triacetin as a transdermal penetration enhancer Download PDFInfo
- Publication number
- WO1996033678A1 WO1996033678A1 PCT/US1996/004845 US9604845W WO9633678A1 WO 1996033678 A1 WO1996033678 A1 WO 1996033678A1 US 9604845 W US9604845 W US 9604845W WO 9633678 A1 WO9633678 A1 WO 9633678A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- matrix patch
- triacetin
- adhesive
- basic drug
- effective amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Definitions
- matrix an active permeant or drug dissolved or suspended in a biocompatible polymeric phase, preferably a pressure sensitive adhesive, that can also contain other ingredients or in which the enhancer is also dissolved or suspended.
- a matrix system usually and preferably comprises an adhesive layer having an impermeable film backing laminated onto the distal surface thereof and, before transdermal application, a release liner on the proximal surface of the adhesive. The film backing protects the polymeric phase of the matrix patch and prevents release of the drug and/or enhancer to the environment.
- Preferred contact adhesives for use in the matrix patch herein are acrylic adhesives, such as TSR (Sekisui Chemical Co., Osaka, Japan) and DuroTak ® adhesives (National Starch & Chemical Co., Bridgewater, N.J.), and polyisobutylene adhesives such as ARcareTM MA-24 (Adhesives Research, Glen Rock, Pennsylvania) .
- the matrix patch device containing a polymer layer, basic drug such as oxybutynin, and triacetin-containing penetration enhancer is brought in contact with the skin or mucosa at a selected application situs and is held in place by a suitable pressure-sensitive adhesive.
- the polymer layer of the matrix patch is an adhesive, but the polymer layer can also be laminated to an adhesive layer or used with an overlay adhesive.
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP96911647A EP0871420B1 (en) | 1995-04-26 | 1996-04-08 | Triacetin as a transdermal penetration enhancer |
AU54467/96A AU696777B2 (en) | 1995-04-26 | 1996-04-08 | Triacetin as a transdermal penetration enhancer |
DE69615399T DE69615399T2 (en) | 1995-04-26 | 1996-04-08 | TRIACETINE FOR INCREASING TRANSDERMAL PENETRATION |
DK96911647T DK0871420T3 (en) | 1995-04-26 | 1996-04-08 | Triacetin as a transdermal penetration promoter |
NZ306249A NZ306249A (en) | 1995-04-26 | 1996-04-08 | matrix patch containing triacetin as a transdermal pentration enhancer |
CA002217888A CA2217888C (en) | 1995-04-26 | 1996-04-08 | Triacetin as a transdermal penetration enhancer |
JP53255096A JP3228341B2 (en) | 1995-04-26 | 1996-04-08 | Triacetin as a penetration enhancer for transdermal delivery of basic drugs |
AT96911647T ATE205694T1 (en) | 1995-04-26 | 1996-04-08 | TRIACETIN TO INCREASE TRANSDERMAL PENETRATION |
DE200512000013 DE122005000013I1 (en) | 1995-04-26 | 1996-04-08 | Triacetin for increasing transdermal penetration. |
MXPA/A/1997/007868A MXPA97007868A (en) | 1995-04-26 | 1997-10-13 | Triacetin as an incrementer of penetrationtransderm |
NL300200C NL300200I1 (en) | 1995-04-26 | 2004-12-21 | Triacetin for increasing transdermal penetration. |
FR05C0008C FR05C0008I2 (en) | 1995-04-26 | 2005-03-17 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/429,757 | 1995-04-26 | ||
US08/429,757 US5601839A (en) | 1995-04-26 | 1995-04-26 | Triacetin as a penetration enhancer for transdermal delivery of a basic drug |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996033678A1 true WO1996033678A1 (en) | 1996-10-31 |
Family
ID=23704623
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/004845 WO1996033678A1 (en) | 1995-04-26 | 1996-04-08 | Triacetin as a transdermal penetration enhancer |
Country Status (19)
Country | Link |
---|---|
US (2) | US5601839A (en) |
EP (1) | EP0871420B1 (en) |
JP (2) | JP3228341B2 (en) |
KR (1) | KR100275593B1 (en) |
CN (3) | CN100374161C (en) |
AR (1) | AR001721A1 (en) |
AT (1) | ATE205694T1 (en) |
AU (1) | AU696777B2 (en) |
CA (1) | CA2217888C (en) |
DE (2) | DE122005000013I1 (en) |
DK (1) | DK0871420T3 (en) |
ES (1) | ES2163012T3 (en) |
FR (1) | FR05C0008I2 (en) |
HK (1) | HK1084320A1 (en) |
NL (1) | NL300200I1 (en) |
NZ (1) | NZ306249A (en) |
PT (1) | PT871420E (en) |
WO (1) | WO1996033678A1 (en) |
ZA (1) | ZA963229B (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998002169A2 (en) * | 1996-07-15 | 1998-01-22 | Alza Corporation | Novel formulations for the administration of fluoxetine |
WO1999048493A1 (en) * | 1998-03-20 | 1999-09-30 | Schwarz Pharma Ag | Transdermal therapeutic system (tts) containing oxybutynin |
WO2000076490A2 (en) * | 1999-06-10 | 2000-12-21 | Sepracor Inc. | Methods and compositions for treating urinary frequency and urgency using optically pure (s)-oxybutynin |
EP1557177A1 (en) * | 1996-11-14 | 2005-07-27 | The Government of the United States of America, as represented by The Secretary of the Army | Antigen for transcutaneous immunisation |
WO2007100757A2 (en) * | 2006-02-27 | 2007-09-07 | Noven Pharmaceuticals, Inc. | Transdermal therapeutic system comprising scopolamine |
WO2008115371A2 (en) | 2007-03-16 | 2008-09-25 | Mylan Technologies, Inc. | Amorphous drug transdermal systems, manufacturing methods, and stabilization |
EP2734198A1 (en) * | 2011-06-24 | 2014-05-28 | Acenda Pharma, Inc. | Method and improved pharmaceutical composition for improving the absorption of an ester prodrug |
WO2014159573A1 (en) * | 2013-03-14 | 2014-10-02 | Noven Pharmaceuticals, Inc | Methylphenidate transdermal compositions with rubber-based adhesives |
EP2772252A4 (en) * | 2011-10-26 | 2015-06-03 | Hisamitsu Pharmaceutical Co | Oxybutynin-containing transdermal absorption preparation |
WO2015139847A1 (en) * | 2014-03-21 | 2015-09-24 | Chironwells Gmbh | 6-(amino acid)-morphinan derivatives in combination with permeation enhancers for use as an orally, rectally, transdermally or nasally administered medicament |
US9731490B2 (en) | 2008-10-02 | 2017-08-15 | Mylan Inc. | Method for making a multilayer adhesive laminate |
Families Citing this family (116)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5474783A (en) * | 1988-03-04 | 1995-12-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
US5633000A (en) * | 1994-06-23 | 1997-05-27 | Axxia Technologies | Subcutaneous implant |
US5785991A (en) * | 1995-06-07 | 1998-07-28 | Alza Corporation | Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate |
US6512010B1 (en) | 1996-07-15 | 2003-01-28 | Alza Corporation | Formulations for the administration of fluoxetine |
US6572880B2 (en) | 1996-10-24 | 2003-06-03 | Pharmaceutical Applications Associates Llc | Methods and transdermal compositions for pain relief |
US6290986B1 (en) | 1996-10-24 | 2001-09-18 | Pharmaceutical Applications Associates, Llc | Method and composition for transdermal administration of pharmacologic agents |
US6479074B2 (en) | 1996-10-24 | 2002-11-12 | Pharmaceutical Applications Associates Llc | Methods and transdermal compositions for pain relief |
JP2001503062A (en) * | 1996-10-30 | 2001-03-06 | セラテック・インコーポレーテッド | Salts of fatty acid esters of lactic acid as permeation enhancers |
US6797276B1 (en) | 1996-11-14 | 2004-09-28 | The United States Of America As Represented By The Secretary Of The Army | Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response |
US20060002949A1 (en) | 1996-11-14 | 2006-01-05 | Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. | Transcutaneous immunization without heterologous adjuvant |
US6203817B1 (en) | 1997-02-19 | 2001-03-20 | Alza Corporation | Reduction of skin reactions caused by transdermal drug delivery |
DE19706824C1 (en) * | 1997-02-21 | 1998-03-26 | Lohmann Therapie Syst Lts | Plaster for transdermal drug delivery |
US5968547A (en) * | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
EP1030668A4 (en) * | 1997-11-10 | 2002-09-25 | Cellegy Pharma Inc | Penetration enhancing and irritation reducing systems |
TW492882B (en) * | 1997-11-28 | 2002-07-01 | Caleb Pharmaceuticals Inc | Cholinergic antagonist plaster composition |
US6210705B1 (en) * | 1997-12-15 | 2001-04-03 | Noven Pharmaceuticals, Nc. | Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate |
US20020102291A1 (en) * | 1997-12-15 | 2002-08-01 | Noven Pharmaceuticals, Inc. | Compositions and method for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate |
EP1459741A1 (en) * | 1997-12-15 | 2004-09-22 | Noven Pharmaceuticals, Inc. | Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with menthylphenidate |
US6727401B1 (en) * | 1998-02-12 | 2004-04-27 | Watson Pharmaceuticals, Inc. | Pressure sensitive adhesive matrix patch for the treatment of onychomycosis |
DE19814084B4 (en) * | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2 agonist-containing transdermal therapeutic system for the treatment of Parkinson's syndrome and process for its preparation |
US6475514B1 (en) | 1998-12-03 | 2002-11-05 | Andrew Blitzer | Athletic patch |
KR100383252B1 (en) * | 1998-12-17 | 2003-07-16 | 주식회사 삼양사 | Transdermal Dosage Compositions Containing Buprenoline and Patches Comprising the Same |
WO2000064434A1 (en) * | 1999-04-26 | 2000-11-02 | Lead Chemical Co., Ltd. | Percutaneous preparations containing oxybutynin |
AU769079B2 (en) | 1999-06-25 | 2004-01-15 | Durham Pharmaceuticals Ltd. | Topical formulations comprising skin penetration agents and the use thereof |
GB9918735D0 (en) * | 1999-08-09 | 1999-10-13 | Straken Limited | Transdermal patches |
US20010049546A1 (en) * | 2000-02-08 | 2001-12-06 | Israel Dvoretzky | Multi-purpose drug and heat therapy treatment system |
US6436428B1 (en) | 2000-03-21 | 2002-08-20 | Enhance Pharmaceuticals, Inc. | Device and method for treating urinary incontinence in females |
MXPA02010542A (en) * | 2000-04-26 | 2003-10-14 | Watson Pharmaceuticals Inc | Minimizing adverse experience associated with oxybutynin therapy. |
US7179483B2 (en) * | 2000-04-26 | 2007-02-20 | Watson Pharmaceuticals, Inc. | Compositions and methods for transdermal oxybutynin therapy |
US7029694B2 (en) * | 2000-04-26 | 2006-04-18 | Watson Laboratories, Inc. | Compositions and methods for transdermal oxybutynin therapy |
US20030124177A1 (en) * | 2000-04-26 | 2003-07-03 | Watson Pharmaceuticals, Inc. | Compositions and methods for transdermal oxybutynin therapy |
US7198801B2 (en) * | 2000-08-03 | 2007-04-03 | Antares Pharma Ipl Ag | Formulations for transdermal or transmucosal application |
EP1307232B1 (en) * | 2000-08-03 | 2007-03-07 | Antares Pharma IPL AG | Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels |
US20070225379A1 (en) * | 2001-08-03 | 2007-09-27 | Carrara Dario Norberto R | Transdermal delivery of systemically active central nervous system drugs |
US8980290B2 (en) | 2000-08-03 | 2015-03-17 | Antares Pharma Ipl Ag | Transdermal compositions for anticholinergic agents |
DE10041478A1 (en) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | New pharmaceutical composition |
DE10060550C1 (en) * | 2000-12-06 | 2002-04-18 | Lohmann Therapie Syst Lts | Transdermal therapeutic system for administration of oxybutynin, especially for treatment of bladder dysfunction, having two-phase matrix layer of active agent-containing droplets dispersed in adhesive |
US6585963B1 (en) * | 2001-02-15 | 2003-07-01 | Watson Pharmaceuticals, Inc. | Nail compositions and methods of administering same |
US20030026830A1 (en) * | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine |
US20030027793A1 (en) * | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal treatment of parkinson's disease |
EP1390383B1 (en) * | 2001-05-11 | 2012-02-29 | Isis Pharmaceuticals, Inc. | Antisense permeation enhancers |
US6913760B2 (en) * | 2001-08-06 | 2005-07-05 | New England Medical Hospitals, Inc. | Drug delivery composition |
AU2002340120A1 (en) * | 2001-10-04 | 2003-04-14 | Cellegy Pharmaceuticals, Inc. | Semisolid topical hormonal compositions and methods for treatment |
US7921999B1 (en) | 2001-12-20 | 2011-04-12 | Watson Laboratories, Inc. | Peelable pouch for transdermal patch and method for packaging |
JP4295467B2 (en) * | 2002-04-12 | 2009-07-15 | 日東電工株式会社 | Patch and method for producing the same |
KR100469995B1 (en) * | 2002-05-20 | 2005-02-05 | 안국약품 주식회사 | Matrix Patch Containing Bronchodilators |
JP4323138B2 (en) * | 2002-06-05 | 2009-09-02 | 日東電工株式会社 | Transdermal preparation and method for producing the same |
US8246979B2 (en) | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system for the administration of rotigotine |
DE10234673B4 (en) * | 2002-07-30 | 2007-08-16 | Schwarz Pharma Ag | Hot-melt TTS for the administration of rotigotine and process for its preparation, and use of rotigotine in the manufacture of a hot-melt TTS |
US8211462B2 (en) * | 2002-07-30 | 2012-07-03 | Ucb Pharma Gmbh | Hot-melt TTS for administering rotigotine |
US8246980B2 (en) * | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system |
EP1386604A1 (en) * | 2002-07-30 | 2004-02-04 | Schwarz Pharma Ag | Improved transdermal delivery system |
AU2003268361A1 (en) * | 2002-08-30 | 2004-03-19 | Watson Pharmaceuticals, Inc. | Drug delivery system for treating urinary incontinence |
DE10251256A1 (en) * | 2002-11-04 | 2004-05-13 | Novosis Ag | Transdermal drug delivery system for oxybutynin |
ATE295726T1 (en) * | 2002-12-02 | 2005-06-15 | Sanol Arznei Schwarz Gmbh | ADMINISTRATION OF ROTIGOTINE FOR THE TREATMENT OF PARKINSON'S DISEASE BY IONTOPHORESIS |
DE10261696A1 (en) | 2002-12-30 | 2004-07-15 | Schwarz Pharma Ag | Device for the transdermal administration of rotigotine base |
ATE461681T1 (en) * | 2003-04-29 | 2010-04-15 | Gen Hospital Corp | METHODS AND DEVICES FOR SUSTAINED RELEASE OF MULTIPLE DRUGS |
DE10338174A1 (en) * | 2003-08-20 | 2005-03-24 | Lts Lohmann Therapie-Systeme Ag | Transdermal drug formulations with drug combinations for the treatment of Parkinson's disease |
MXPA06003316A (en) * | 2003-10-10 | 2006-06-08 | Antares Pharma Ipl Ag | Transdermal pharmaceutical formulation for minimizing skin residues. |
WO2005077364A1 (en) * | 2004-02-18 | 2005-08-25 | Yamanouchi Pharmaceutical Co., Ltd. | Transdermal solifenacin preparation and method of improving transdermal permeability thereof |
US7425340B2 (en) * | 2004-05-07 | 2008-09-16 | Antares Pharma Ipl Ag | Permeation enhancing compositions for anticholinergic agents |
EP1611882B1 (en) * | 2004-06-01 | 2010-04-07 | Hisamitsu Pharmaceutical Co., Inc. | Adhesive patch |
CA2580329C (en) | 2004-09-13 | 2015-01-06 | Chrono Therapeutics Inc. | Biosynchronous transdermal drug delivery |
US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
US8252319B2 (en) | 2004-10-21 | 2012-08-28 | Durect Corporation | Transdermal delivery system for sufentanil |
ATE471146T1 (en) | 2004-10-21 | 2010-07-15 | Durect Corp | TRANSDERMAL DELIVERY SYSTEMS |
US20070053965A1 (en) * | 2005-02-25 | 2007-03-08 | Gruenenthal Gmbh | Kit comprising a plaster, optionally containing an active substance, and an agent that at least partially reduces skin irritation |
WO2006127905A2 (en) | 2005-05-24 | 2006-11-30 | Chrono Therapeutics, Inc. | Portable drug delivery device |
WO2006125642A1 (en) | 2005-05-27 | 2006-11-30 | Antares Pharma Ipl Ag | Methods and apparatus for transdermal or transmucosal application of testosterone |
US20070065494A1 (en) * | 2005-08-03 | 2007-03-22 | Watson Laboratories, Inc. | Formulations and Methods for Enhancing the Transdermal Penetration of a Drug |
US10137135B2 (en) * | 2005-08-15 | 2018-11-27 | Allergan Sales, Llc | Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith |
JP5037831B2 (en) * | 2006-02-15 | 2012-10-03 | 久光製薬株式会社 | External patch for improving cohesion and sustained release |
NZ571460A (en) | 2006-04-21 | 2010-10-29 | Antares Pharma Ipl Ag | Methods of treating hot flashes with formulations for transdermal or transmucosal application |
WO2007143674A2 (en) * | 2006-06-05 | 2007-12-13 | Verus Pharmaceuticals, Inc. | Methods for buccal, lingual or sublingual dosing regimens of epinephrine for the treatment of allergic emergencies |
US20070293582A1 (en) * | 2006-06-05 | 2007-12-20 | Malcolm Hill | Epinephrine dosing regimens comprising buccal, lingual or sublingual and injectable dosage forms |
WO2008067991A2 (en) * | 2006-12-08 | 2008-06-12 | Antares Pharma Ipl Ag | Skin-friendly drug complexes for transdermal administration |
ATE482703T1 (en) * | 2006-12-28 | 2010-10-15 | Kaken Pharma Co Ltd | GEL COMPOSITION FOR TREATING MYCOSIS |
NZ552816A (en) * | 2007-01-24 | 2009-05-31 | Bomac Research Ltd | Formulation for transdermal administration of antihyperthyroid drug comprising a penetration enhancer selected from oleic acid, d-limonene, pyrrolidones, a C2-C8 alcohol, glycol ethers, triacetin and combinations thereof |
KR101612901B1 (en) | 2007-03-02 | 2016-04-15 | 테이카 세이야쿠 가부시키가이샤 | Medicinal composition for transdermal absorption, medicinal composition storing unit and transdermal absorption preparation using the same |
US10183001B1 (en) * | 2007-05-22 | 2019-01-22 | Pisgah Laboratories, Inc. | Opioid and attention deficit hyperactivity disorder medications possessing abuse deterrent and anti-dose dumping safety features |
WO2009018356A1 (en) * | 2007-07-30 | 2009-02-05 | Medacure International, Inc. | Immune system modulator formulation |
US20090098191A1 (en) * | 2007-10-16 | 2009-04-16 | Anderson Christopher G | Use of bases to stabilize transdermal formulations |
AU2008336605B2 (en) * | 2007-12-12 | 2013-06-27 | Teikoku Seiyaku Co., Ltd. | Loxoprofen-containing aqueous plaster |
US20090297591A1 (en) * | 2008-05-30 | 2009-12-03 | Orient Pharma Co., Ltd. | Compositions And Methods For The Transdermal Delivery Of Pharmaceutical Compounds |
US8404255B2 (en) * | 2008-07-29 | 2013-03-26 | Matt Gibson | System and method for transdermal drug delivery |
JP5155128B2 (en) * | 2008-12-11 | 2013-02-27 | 日東電工株式会社 | Methylphenidate patch preparation |
US8920392B2 (en) | 2009-05-05 | 2014-12-30 | Watson Laboratories, Inc. | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions |
US8840922B2 (en) * | 2009-10-21 | 2014-09-23 | Teikoku Seiyaku Co., Ltd. | Transdermally absorbable donepezil-containing preparation |
KR101738200B1 (en) | 2009-12-15 | 2017-05-19 | 데이고꾸세이약꾸가부시끼가이샤 | Transdermal preparation containing basic anti-inflammatory agent |
CA2796575C (en) | 2010-04-13 | 2018-05-15 | Relmada Therapeutics, Inc. | Dermal pharmaceutical compositions of 1-methyl-2',6'-pipecoloxylidide and method of use |
EP2563123B1 (en) | 2010-04-30 | 2018-04-25 | Merck Sharp & Dohme Corp. | Novel beta 3 adrenergic receptor agonists |
FR2972923B1 (en) * | 2011-03-25 | 2013-08-23 | Urgo Lab | FILMOGENIC COMPOSITION CONTAINING A SOLAR FILTER, ITS USE FOR THE TREATMENT OF SCARS |
US11786455B2 (en) | 2011-05-10 | 2023-10-17 | Itochu Chemical Frontier Corporation | Non-aqueous patch |
US9283174B2 (en) | 2011-05-10 | 2016-03-15 | Tatsuya Mori | Non-aqueous patch |
US9925264B2 (en) | 2011-05-10 | 2018-03-27 | Itochu Chemical Frontier Corporation | Non-aqueous patch |
WO2013006643A1 (en) | 2011-07-06 | 2013-01-10 | The Parkinson's Institute | Compositions and methods for treatment of symptoms in parkinson's disease patients |
HUE039266T2 (en) | 2011-09-27 | 2018-12-28 | Itochu Chemical Frontier Corp | Non-aqueous patch |
US20130266643A1 (en) * | 2012-04-10 | 2013-10-10 | Hpo Life Sciences, Inc. | Compositions comprising glyceryl-triacetate (GTA) and uses in human performance optimization and thermogenesis |
ES2706994T3 (en) * | 2012-09-03 | 2019-04-02 | Daiichi Sankyo Co Ltd | Orally extended-release pharmaceutical composition containing hydromorphone hydrochloride |
SG10202011046RA (en) | 2012-09-21 | 2020-12-30 | Intensity Therapeutics Inc | Method of treating cancer |
US9072682B2 (en) | 2012-12-31 | 2015-07-07 | Mylan Inc. | Transdermal dosage form for low-melting point active agent |
CN103919754B (en) * | 2013-01-15 | 2018-11-06 | 江苏康倍得药业股份有限公司 | Oxybutynin pharmaceutical composition and its application |
US10105487B2 (en) | 2013-01-24 | 2018-10-23 | Chrono Therapeutics Inc. | Optimized bio-synchronous bioactive agent delivery system |
EP4122460A1 (en) | 2015-01-09 | 2023-01-25 | Chase Pharmaceuticals Corporation | Oxybutynin transdermal therapeutic system combination |
US10213586B2 (en) | 2015-01-28 | 2019-02-26 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
AU2016228779A1 (en) | 2015-03-12 | 2017-09-07 | Chrono Therapeutics Inc. | Craving input and support system |
US11285306B2 (en) | 2017-01-06 | 2022-03-29 | Morningside Venture Investments Limited | Transdermal drug delivery devices and methods |
JP2019034905A (en) * | 2017-08-17 | 2019-03-07 | コスメディ製薬株式会社 | Dehydroacetic acid-containing percutaneous absorption preparation |
WO2019089523A1 (en) * | 2017-10-30 | 2019-05-09 | Theracaine Llc | Hydrophobic acid addition salts and pharmaceutical formulations thereof |
KR101975677B1 (en) | 2017-11-20 | 2019-05-07 | 양진석 | Fluff removal device of circular knitting machine |
JP7420797B2 (en) | 2018-05-29 | 2024-01-23 | モーニングサイド ベンチャー インベストメンツ リミテッド | Drug delivery methods and systems |
KR102320656B1 (en) | 2018-10-26 | 2021-11-02 | 경상국립대학교 산학협력단 | A biological method for preparing acetins |
CN113384558A (en) * | 2021-02-01 | 2021-09-14 | 深圳普洛美康材料有限公司 | Transdermal patch for delivering cannabis active substance |
JP2022122784A (en) | 2021-02-10 | 2022-08-23 | コスメディ製薬株式会社 | Antioxidant-containing transdermal absorption preparation |
KR20230026232A (en) | 2021-08-17 | 2023-02-24 | 신신제약 주식회사 | Percutaneous absorption system comprising oxybutynin |
CN113749968A (en) * | 2021-10-26 | 2021-12-07 | 奥易生物科技(杭州)有限公司 | Cosmetic capable of being quickly absorbed through skin and preparation method thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4666926A (en) * | 1986-02-27 | 1987-05-19 | Warner-Lambert Company | Transdermal formulations |
US4857313A (en) * | 1987-05-28 | 1989-08-15 | Warner-Lambert Company | Transdermal drug delivery device comprising copolymers of N-morpholinoethyl methacrylate and 2-hydroxylmethacrylate |
WO1993009783A1 (en) * | 1991-11-15 | 1993-05-27 | Ss Pharmaceutical Co., Ltd. | Anti-inflammatory and analgesic plaster |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US466926A (en) * | 1892-01-12 | Advertising device | ||
US4336262A (en) * | 1973-02-23 | 1982-06-22 | Fisons Ltd. | Pour-on veterinary anthelmintic |
DE3581188D1 (en) * | 1984-07-24 | 1991-02-07 | Key Pharma | ADHESIVE LAYER FOR TRANSDERMAL RELEASE. |
US4895727A (en) * | 1985-05-03 | 1990-01-23 | Chemex Pharmaceuticals, Inc. | Pharmaceutical vehicles for exhancing penetration and retention in the skin |
US4908389A (en) * | 1986-08-27 | 1990-03-13 | Warner-Lambert Company | Penetration enhancement system |
JPH0676327B2 (en) * | 1987-04-14 | 1994-09-28 | 株式会社大塚製薬工場 | Steroid ointment formulation |
US4879297A (en) * | 1987-06-01 | 1989-11-07 | Warner-Lambert Company | Fatty acids and their small chain esters as penetration enhancers in aqueous systems |
US4789547A (en) * | 1987-06-17 | 1988-12-06 | Warner-Lambert Company | Transdermal matrix system |
US4814173A (en) * | 1987-09-08 | 1989-03-21 | Warner-Lambert Company | Silicone elastomer transdermal matrix system |
JP2526256B2 (en) * | 1987-11-17 | 1996-08-21 | 清水建設株式会社 | Vibration suppression device for structures |
US5019395A (en) * | 1988-03-08 | 1991-05-28 | Warner-Lambert Company | Compositions with enhanced penetration |
DE3913954A1 (en) * | 1989-04-27 | 1990-10-31 | Stief Georg | MEDICINES FOR TREATING ERECTILE DYSFUNCTIONS |
JP3130350B2 (en) * | 1991-11-28 | 2001-01-31 | 積水化学工業株式会社 | Transdermal formulation |
TW224048B (en) * | 1992-03-30 | 1994-05-21 | Hoechst Roussel Pharma | |
ES2137993T3 (en) * | 1992-06-11 | 2000-01-01 | Theratech Inc | THE USE OF GLYCERINE TO MODERATE THE TRANSDERMAL CONTRIBUTION OF MEDICINES. |
JPH08245377A (en) * | 1995-03-15 | 1996-09-24 | Yamanouchi Pharmaceut Co Ltd | Pharmaceutical preparation for percutaneous absorption |
JPH09309783A (en) * | 1996-05-20 | 1997-12-02 | Chisso Corp | Improved soil collapse type coated granular fertilizer |
-
1995
- 1995-04-26 US US08/429,757 patent/US5601839A/en not_active Expired - Lifetime
-
1996
- 1996-04-08 CN CNB2005100719966A patent/CN100374161C/en not_active Expired - Lifetime
- 1996-04-08 PT PT96911647T patent/PT871420E/en unknown
- 1996-04-08 CA CA002217888A patent/CA2217888C/en not_active Expired - Lifetime
- 1996-04-08 CN CNA2004100392112A patent/CN1507918A/en active Pending
- 1996-04-08 DE DE200512000013 patent/DE122005000013I1/en active Pending
- 1996-04-08 DK DK96911647T patent/DK0871420T3/en active
- 1996-04-08 KR KR1019970707309A patent/KR100275593B1/en not_active IP Right Cessation
- 1996-04-08 AT AT96911647T patent/ATE205694T1/en active
- 1996-04-08 NZ NZ306249A patent/NZ306249A/en not_active IP Right Cessation
- 1996-04-08 CN CNB961934565A patent/CN1143688C/en not_active Expired - Lifetime
- 1996-04-08 ES ES96911647T patent/ES2163012T3/en not_active Expired - Lifetime
- 1996-04-08 WO PCT/US1996/004845 patent/WO1996033678A1/en active IP Right Grant
- 1996-04-08 DE DE69615399T patent/DE69615399T2/en not_active Expired - Lifetime
- 1996-04-08 EP EP96911647A patent/EP0871420B1/en not_active Expired - Lifetime
- 1996-04-08 JP JP53255096A patent/JP3228341B2/en not_active Expired - Lifetime
- 1996-04-08 AU AU54467/96A patent/AU696777B2/en not_active Expired
- 1996-04-23 ZA ZA963229A patent/ZA963229B/en unknown
- 1996-04-26 AR AR33630496A patent/AR001721A1/en active IP Right Grant
-
1997
- 1997-01-03 US US08/775,367 patent/US5834010A/en not_active Expired - Lifetime
-
2000
- 2000-07-04 JP JP2000201747A patent/JP4511691B2/en not_active Expired - Lifetime
-
2004
- 2004-12-21 NL NL300200C patent/NL300200I1/en unknown
-
2005
- 2005-03-17 FR FR05C0008C patent/FR05C0008I2/fr active Active
-
2006
- 2006-03-04 HK HK06102837A patent/HK1084320A1/en not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4666926A (en) * | 1986-02-27 | 1987-05-19 | Warner-Lambert Company | Transdermal formulations |
US4857313A (en) * | 1987-05-28 | 1989-08-15 | Warner-Lambert Company | Transdermal drug delivery device comprising copolymers of N-morpholinoethyl methacrylate and 2-hydroxylmethacrylate |
WO1993009783A1 (en) * | 1991-11-15 | 1993-05-27 | Ss Pharmaceutical Co., Ltd. | Anti-inflammatory and analgesic plaster |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998002169A2 (en) * | 1996-07-15 | 1998-01-22 | Alza Corporation | Novel formulations for the administration of fluoxetine |
WO1998002169A3 (en) * | 1996-07-15 | 1998-03-12 | Alza Corp | Novel formulations for the administration of fluoxetine |
EP1557177A1 (en) * | 1996-11-14 | 2005-07-27 | The Government of the United States of America, as represented by The Secretary of the Army | Antigen for transcutaneous immunisation |
WO1999048493A1 (en) * | 1998-03-20 | 1999-09-30 | Schwarz Pharma Ag | Transdermal therapeutic system (tts) containing oxybutynin |
JP2002507565A (en) * | 1998-03-20 | 2002-03-12 | シュバルツ ファルマ アクチェンゲゼルシャフト | Transdermal therapeutic system (TTS) containing oxybutynin |
AU745923B2 (en) * | 1998-03-20 | 2002-04-11 | Schwarz Pharma Ag | Transdermal therapeutic system (TTS) containing oxybutynin |
US6555129B1 (en) | 1998-03-20 | 2003-04-29 | Schwarz Pharma Ag | Transdermal therapeutic system (TTS) containing oxybutynin |
WO2000076490A2 (en) * | 1999-06-10 | 2000-12-21 | Sepracor Inc. | Methods and compositions for treating urinary frequency and urgency using optically pure (s)-oxybutynin |
WO2000076490A3 (en) * | 1999-06-10 | 2002-03-21 | Sepracor Inc | Methods and compositions for treating urinary frequency and urgency using optically pure (s)-oxybutynin |
WO2007100757A3 (en) * | 2006-02-27 | 2007-10-18 | Noven Pharma | Transdermal therapeutic system comprising scopolamine |
WO2007100757A2 (en) * | 2006-02-27 | 2007-09-07 | Noven Pharmaceuticals, Inc. | Transdermal therapeutic system comprising scopolamine |
US8715723B2 (en) | 2006-02-27 | 2014-05-06 | Noven Pharmaceuticals, Inc. | Compositions and methods for delivery of amino-functional drugs |
WO2008115371A2 (en) | 2007-03-16 | 2008-09-25 | Mylan Technologies, Inc. | Amorphous drug transdermal systems, manufacturing methods, and stabilization |
WO2008115371A3 (en) * | 2007-03-16 | 2009-08-27 | Mylan Technologies, Inc. | Amorphous drug transdermal systems, manufacturing methods, and stabilization |
US9731490B2 (en) | 2008-10-02 | 2017-08-15 | Mylan Inc. | Method for making a multilayer adhesive laminate |
US10272656B2 (en) | 2008-10-02 | 2019-04-30 | Mylan Inc. | Method for making a multilayer adhesive laminate |
EP2734198A1 (en) * | 2011-06-24 | 2014-05-28 | Acenda Pharma, Inc. | Method and improved pharmaceutical composition for improving the absorption of an ester prodrug |
EP2734198A4 (en) * | 2011-06-24 | 2015-04-15 | Acenda Pharma Inc | Method and improved pharmaceutical composition for improving the absorption of an ester prodrug |
EP2772252A4 (en) * | 2011-10-26 | 2015-06-03 | Hisamitsu Pharmaceutical Co | Oxybutynin-containing transdermal absorption preparation |
WO2014159573A1 (en) * | 2013-03-14 | 2014-10-02 | Noven Pharmaceuticals, Inc | Methylphenidate transdermal compositions with rubber-based adhesives |
WO2015139847A1 (en) * | 2014-03-21 | 2015-09-24 | Chironwells Gmbh | 6-(amino acid)-morphinan derivatives in combination with permeation enhancers for use as an orally, rectally, transdermally or nasally administered medicament |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5601839A (en) | Triacetin as a penetration enhancer for transdermal delivery of a basic drug | |
CA2135925C (en) | Use of glycerin in moderating transdermal drug delivery | |
US5985317A (en) | Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents | |
US5906830A (en) | Supersaturated transdermal drug delivery systems, and methods for manufacturing the same | |
CA2252772C (en) | Transdermal delivery of basic drugs using nonpolar adhesive systems and acidic solubilizing agents | |
JP2550441B2 (en) | Skin permeability promoting composition | |
US5641504A (en) | Skin permeation enhancer compositions using glycerol monolinoleate | |
AU717183B2 (en) | Fatty acid esters of lactic acid salts as permeation enhancers | |
JP2604097B2 (en) | Method and system for transdermal drug administration using sorbitan esters as skin penetration enhancers | |
TW201431572A (en) | Compositions and methods for transdermal delivery of hormones and other medicinal agents | |
JP3980634B2 (en) | Pharmaceutical composition for systemic transdermal administration comprising the active substance morphine-6-glucuronide | |
JPH09268123A (en) | Cataplasm for local anesthesia | |
JPH05279254A (en) | Clonidine dermal administration pharmaceutical preparation | |
MXPA97007868A (en) | Triacetin as an incrementer of penetrationtransderm | |
KR20020037616A (en) | Transdermal ketorolac formulation for increasing transdermal absorption of ketorolac | |
IE921615A1 (en) | Skin permeation enhancer compositions using glycerol¹monolinoleate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 96193456.5 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 306249 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996911647 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2217888 Country of ref document: CA Ref document number: 2217888 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1997/007868 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019970707309 Country of ref document: KR |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1996911647 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019970707309 Country of ref document: KR |
|
WWR | Wipo information: refused in national office |
Ref document number: 1019970707309 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1996911647 Country of ref document: EP |